未登录 Benefit of a lower dose of Epoetin Theta (ET) in real life for the treatment of chemotherapy-induced anemia (CIA) Bugat, R.; Rouge, M. E.; Mouysset, J. L.; Badinand, D.; Assaf, E.; Fleck, E.; Guita, S.; Hussam, S.; Benbrahim, O.; Askoul, W. 分享 收藏
分享 收藏
Supportive care organisation in France: An in depth study by the French speaking association for supportive care in cancer (AFSOS) Scotte, F.; Herve, C.; Oudard, S.; Bugat, M. E.; Bugat, R.; Farsi, F.; Namer, M.; Tourani, J. M.; Tournigand, C.; Yazbek, G.; Richard, S.; Krakowski, I. 分享 收藏
Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009-2010: The AnemOnHe study Spielmann, Marc; Luporsi, Elisabeth; Ray-Coquard, Isabelle; de Botton, Stephane; Azria, David; Lasocki, Sigismond; Lafuma, Antoine; Mahi, Lamine; Deray, Gilbert; Bugat, Roland 分享 收藏
分享 收藏
Effect of XELOX on functional ability among elderly patients with metastatic colorectal cancer: Results from the FNCLCC/GERICO 02 phase II study Rousseau, Frederique; Bugat, Roland; Ducreux, Michel; Cvitkovic, Frederique; Carola, Elisabeth; Gisselbrecht, Mathilde; Viret, Frederic; Esterni, Benjamin; Geneve, Jean; Brain, Etienne 分享 收藏
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial Curran, Desmond; Pozzo, Carmelo; Zaluski, Jerzy; Dank, Magdalena; Barone, Carlo; Valvere, Vahur; Yalcin, Suayib; Peschel, Christian; Wenczl, Miklos; Goker, Erdem; Bugat, Roland 分享 收藏
A phase III randomised trial of LV5FU2+irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802) LV5FU2伊立替康与LV5FU2单独治疗辅助高危结肠癌的III期随机试验 (FNCLCC Accord02/FFCD9802) Ychou, M.; Raoul, J. -L.; Douillard, J. -Y.; Gourgou-Bourgade, S.; Bugat, R.; Mineur, L.; Viret, F.; Becouarn, Y.; Bouche, O.; Gamelin, E.; Ducreux, M.; Conroy, T.; Seitz, J. -F.; Bedenne, L.; Kramar, A. 分享 收藏
Patient-Reported Outcomes as a Component of the Primary Endpoint in a Double-Blind, Placebo-Controlled Trial in Advanced Pancreatic Cancer Eckhardt, S. Gail; De Porre, Peter; Smith, David; Maurel, Joan; Steward, William P.; Bouche, Olivier; van de Velde, Helgi; Michiels, Bart; Bugat, Roland 分享 收藏
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction Dank, M.; Zaluski, J.; Barone, C.; Valvere, V.; Yalcin, S.; Peschel, C.; Wenczl, M.; Goker, E.; Cisar, L.; Wang, K.; Bugat, R. 分享 收藏
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients Van Cutsem, E.; Verslype, C.; Beale, P.; Clarke, S.; Bugat, R.; Rakhit, A.; Fettner, S. H.; Brennscheidt, U.; Feyereislova, A.; Feyereislova, A.; Delord, J. -P. 分享 收藏
分享 收藏
Capecitabine (XELODAO®, X) and oxaliplatine (ELOXATINO®, LOHP) regimen (XELOX) in elderly patients with metastatic colorectal cancer (MCRC):: a FNCLCC French Collaborative Group GERICO 02 phase II study Rousseau, F.; Bugat, R.; Ducreux, M.; Cvitkovic, F.; Carola, E.; Gisselbrecht, M.; Esterni, B.; Gouttenoire, F.; Viret, F. 分享 收藏
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? Massard, C.; Voigt, J-J; Laplanche, A.; Culine, S.; Lortholary, A.; Bugat, R.; Theodore, C.; Priou, F.; Kaminsky, M-C; Lesimple, T.; Pivot, X.; Coudert, B.; Douillard, J-Y; Merrouche, Y.; Fizazi, K. 分享 收藏
Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI):: first-line therapy for metastatic colorectal cancer Delord, J-P; Bennouna, J.; Artru, P.; Perrier, H.; Husseini, F.; Desseigne, F.; Francois, E.; Faroux, R.; Smith, D.; Piedbois, P.; Naman, H.; Douillard, J. Y.; Bugat, R. 分享 收藏
Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma Delord, JP; Allal, C; Canal, M; Mery, E; Rochaix, P; Hennebelle, I; Pradines, A; Chatelut, E; Bugat, R; Guichard, S; Canal, P 分享 收藏
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours Delord, JP; Pierga, JY; Dieras, V; Bertheault-Cvitkovic, F; Turpin, FL; Lokiec, F; Lochon, I; Chatelut, E; Canal, P; Guimbaud, R; Mery-Mignard, D; Cornen, X; Mouri, Z; Bugat, R 分享 收藏
分享 收藏
Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma:: results of a randomized phase II study 伊立替康与5-氟尿嘧啶和亚叶酸或顺铂联合治疗晚期胃或食管-胃交界处腺癌: 一项随机II期研究的结果 Pozzo, C; Barone, C; Szanto, J; Padi, E; Pesche, C; Bükki, J; Gorbunova, V; Valvere, V; Zaluski, J; Biakhov, M; Zuber, E; Jacques, C; Bugat, R 分享 收藏
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-fluorouracil and infusional 5-fluorouracil alone in advanced pancreatic carcinoma patients -: Response Ducreux, M; Mitry, E; Ould-Kaci, A; Boige, V; Seitz, JF; Bugat, R; Breau, JL; Bouché, O; Etienne, PL; Tigaud, JM; Morvan, F; Cvitkovic, E; Rougier, P 分享 收藏
.png){kind=icon}
未登录.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
